Research Highlights: Highlights from the Latest Articles in Personalized Cardiovascular Medicine

• Trusheim MR , BerndtER, DouglasFL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6(4) , 287–293 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor AL , ZiescheS, YancyC et al.; African–American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351(20) , 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S , SleightP, PogueJ, BoschJ, DaviesR, DagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3) , 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386) , 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Braunwald E , DomanskiMJ, FowlerSE et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20) , 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Dagenais GR , PogueJ, FoxK, SimoonsML, YusufS. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet368(9535) , 581–588 (2006).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Benjamin EJ, Bonow RO et al.; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation124(22) , 2458–2473 (2011).
   PubMed Web of Science ®Google Scholar

▪ Website

• World Heart Federation and the World Stroke Organization. Global atlas on cardiovascular disease prevention and control. http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf
   Google Scholar

• Braunwald E , DomanskiMJ, FowlerSE et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20) , 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Sabatine MS , MorrowDA, de Lemos JA et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation125(2) , 233–240 (2012).
   PubMed Web of Science ®Google Scholar
• Levin ER , GardnerDG, SamsonWK. Natriuretic peptides. N. Engl. J. Med.339(5) , 321–328 (1998).
   PubMed Web of Science ®Google Scholar
• Bunton DC , PetrieMC, HillierC, JohnstonF, McMurrayJJ. The clinical relevance of adrenomedullin: a promising profile? Pharmacol. Ther.103(3) , 179–201 (2004).
   PubMed Web of Science ®Google Scholar
• Spieker LE , NollG, RuschitzkaFT, LuscherTF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol.37(6) , 1493–1505 (2001).
   PubMed Web of Science ®Google Scholar

• Rigat B , HubertC, Alhenc-GelasF, CambienF, CorvolP, SoubrierF. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest.86(4) , 1343–1346 (1990).
   PubMed Web of Science ®Google Scholar
• Sayed-Tabatabaei FA , OostraBA, IsaacsA, van Duijn CM, Witteman JC. ACE polymorphisms. Circ. Res.98(9) , 1123–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Martin MM , BuckenbergerJA, JiangJ et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J. Biol. Chem. 282(33) , 24262–24269 (2007).
   PubMed Web of Science ®Google Scholar
• White PC , RaineyWE. Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. J. Clin. Endocrinol. Metab.90(2) , 1252–1255 (2005).
   PubMed Web of Science ®Google Scholar
• Borzyszkowska J , Stanislawska-SachadynA, WirtweinM et al. Angiotensin converting enzyme gene polymorphism is associated with severity of coronary artery disease in men with high total cholesterol levels. J. Appl. Genet. 53(2) , 175–182 (2012).
   PubMed Web of Science ®Google Scholar

• Lakka HM , LaaksonenDE, LakkaTA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21) , 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM , CleemanJI, DanielsSR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17) , 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Ueno H , YamaguchiH, MizutaM, NakazatoM. The role of PYY in feeding regulation. Regul. Pept.145(1–3) , 12–16 (2008).
   PubMedGoogle Scholar
• Masoudi-Kazemabad A , JamialahmadiK, MoohebatiM et al. High frequency of neuropeptide Y Leu7Pro polymorphism in an Iranian population and its association with coronary artery disease. Gene 496(1) , 22–27 (2012).
   PubMed Web of Science ®Google Scholar
• Masoudi-Kazemabad A , JamialahmadiK, MoohebatiM et al. Neuropeptide Y Leu7Pro polymorphism associated with the metabolic syndrome and its features in patients with coronary artery disease. Angiology doi:10.1177/0003319711435149 (2012) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar